BIIB vs. BIO: Biogen vs. Bio-Rad Laboratories Stock Comparison
How do Biogen (BIIB) and Bio-Rad Laboratories (BIO) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Biogen (BIIB) and Bio-Rad Laboratories (BIO) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BIIB is classified in Biotechnology while BIO is classified in Life Sciences Tools & Services.
| Profile Item | BIIB | BIO |
|---|---|---|
| Name | Biogen Inc. | Bio-Rad Laboratories Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Life Sciences Tools & Services |
| GICS Sub-Industry | Biotechnology | Life Sciences Tools & Services |
| Market Capitalization | 36.71 billion USD | 10.26 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | NYSE |
| Listing Date | September 17, 1991 | February 27, 1980 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | BIIB | BIO |
|---|---|---|
| Total Return (1Y) | 65.44% | 28.31% |
| Total Return (3Y, Annualized) | 4.62% | 8.52% |
| Total Return (5Y, Annualized) | -0.96% | -11.74% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | BIIB | BIO |
|---|---|---|
| Volatility (1Y, Annualized) | 34.58% | 36.50% |
| Beta (5Y) | 0.08 | 1.03 |
| Max Drawdown (5Y) | -64.35% | -72.24% |
| Avg. Volume (3M) | 1.05M | 250.78K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | BIIB | BIO |
|---|---|---|
| Sharpe Ratio (1Y) | 1.77 | 0.66 |
| Sortino Ratio (1Y) | 2.77 | 0.98 |
Profitability
ROE (TTM)
Bio-Rad Laboratories (BIO) at 14.27% sits in the top ROE quartile, while Biogen (BIIB) at 1.87% is closer to the peer norm — stronger capital efficiency for BIO.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.87%
- Max
- 109.18%
- Q3
- 6.23%
- BIIB
- 1.87%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
14.27%
- Max
- 109.18%
- BIO
- 14.27%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Bio-Rad Laboratories (BIO) at 39.45% converts revenue to bottom-line profit above its industry’s benchmark range, while Biogen (BIIB) at 3.38% keeps roughly the typical share for its industry.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.38%
- Max
- 18.05%
- Q3
- 4.78%
- BIIB
- 3.38%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
39.45%
- BIO
- 39.45%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Biogen (BIIB) at 24.12% operates in the top operating margin quartile, ahead of Bio-Rad Laboratories (BIO) at 11.82%, which runs around its industry’s norm.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
24.12%
- Max
- 83.12%
- BIIB
- 24.12%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
11.82%
- Max
- 83.12%
- Q3
- 14.77%
- BIO
- 11.82%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | BIIB | BIO |
|---|---|---|
| ROE (TTM) | 1.87% | 14.27% |
| ROA (TTM) | 4.94% | 1.50% |
| Net Margin (TTM) | 3.38% | 39.45% |
| Operating Margin (TTM) | 24.12% | 11.82% |
| Gross Margin (TTM) | 75.77% | 52.19% |
Growth
Revenue Growth
Both Biogen (BIIB) at 2.22% and Bio-Rad Laboratories (BIO) at 0.65% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Only one side can be read here: Biogen (BIIB) reports EPS growth of -21.38%, ranked against its industry; Bio-Rad Laboratories (BIO) has no EPS growth figure this period.
Growth Metrics
| Metric | BIIB | BIO |
|---|---|---|
| Revenue Growth (YoY) | 2.22% | 0.65% |
| Revenue Growth (3Y CAGR) | -0.94% | -2.68% |
| EPS Growth (YoY) | -21.38% | -- |
| EPS Growth (3Y CAGR) | -25.04% | -- |
Financial Strength
Current Ratio (MRQ)
Bio-Rad Laboratories (BIO) at 3.18 keeps current ratio within its industry’s typical mid-range, while Biogen (BIIB) at 1.95 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for BIIB.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.95
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- BIIB
- 1.95
- Min
- 0.10
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.18
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- BIO
- 3.18
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Both Biogen (BIIB) at 0.41 and Bio-Rad Laboratories (BIO) at 0.18 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.41
- Max
- 1.42
- Q3
- 0.65
- BIIB
- 0.41
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.18
- Max
- 1.42
- Q3
- 0.65
- BIO
- 0.18
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | BIIB | BIO |
|---|---|---|
| Current Ratio (MRQ) | 1.95 | 3.18 |
| Debt / Equity (MRQ) | 0.41 | 0.18 |
| Net Debt / EBITDA | 1.97 | -0.73 |
Dividends
Dividend Yield (TTM)
Neither Biogen (BIIB) nor Bio-Rad Laboratories (BIO) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIIB
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Biogen (BIIB) nor Bio-Rad Laboratories (BIO) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIIB
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | BIIB | BIO |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Bio-Rad Laboratories (BIO) at 10.14 sits in the cheaper P/E ratio quartile, while Biogen (BIIB) at 107.51 trades above its peer range — a wide earnings-valuation gap relative to industry peers.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
107.51
- BIIB
- 107.51
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
10.14
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- BIO
- 10.14
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Biogen (BIIB) at 3.57 and Bio-Rad Laboratories (BIO) at 3.96 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.57
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- BIIB
- 3.57
- Q1
- 3.01
- Min
- 0.01
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.96
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- BIO
- 3.96
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Bio-Rad Laboratories (BIO) at 1.35 sits in the lower P/B ratio quartile against book while Biogen (BIIB) at 1.94 is valued near its industry’s middle — BIO is cheaper on assets, though weigh it against ROE and asset quality.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.94
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- BIIB
- 1.94
- Q1
- 1.69
- Min
- -5.59
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.35
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- BIO
- 1.35
- Min
- -5.59
Valuation Metrics
| Metric | BIIB | BIO |
|---|---|---|
| P/E Ratio (TTM) | 107.51 | 10.14 |
| P/S Ratio (TTM) | 3.57 | 3.96 |
| P/B Ratio (MRQ) | 1.94 | 1.35 |
| Free Cash Flow Yield (TTM) | 2.20% | 2.65% |